This study aims to evaluate the efficacy and safety of DWP16001 in type 2 diabetic nephropathy with moderate renal impairment patients (CKD stage 3)
Men and women aged 19 years or older as of the date of written consent.
Patients with type 2 diabetes who have been on up to 3 antidiabetic medications at a stable dosage and regimen for at least 8 weeks prior to the Pre-Baseline Visit (Visit 1-1). For insulin, a fluctuation of within 10% during the 8 weeks prior to the Pre-Baseline Visit (Visit 1-1) is allowed.
Patients with a BMI of 18 to 45 kg/m² at the Screening Visit (Visit 1).
HbA1c: 7.0% ≤ HbA1c ≤ 10.0%
Individuals diagnosed with renal diseases other than diabetic chronic kidney disease
Patients with uncontrolled hypertension (SBP ≥ 180 mmHg or DBP ≥ 110 mmHg)
Individuals diagnosed with type 1 diabetes (insulin-dependent diabetes) or diabetic ketoacidosis
Individuals who are undergoing dialysis at the time of the Screening Visit (Visit 1) or have a history of renal transplantation or medically significant renal disease/surgery (e.g., renal vascular occlusive disease, nephrectomy)